Unravelling the Smokers’ Paradox: Cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis and haemostasis 2014-06, Vol.111 (6), p.1187-1190
Hauptverfasser:	Gurbel, Paul A., Baker, Brian A., Bailey, William L., Bliden, Kevin P., Tantry, Udaya S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine - analogs & derivatives Adenosine - therapeutic use Administration, Oral Biological and medical sciences Blood coagulation. Blood cells Cardiology. Vascular system Clinical Trials as Topic Coronary Artery Disease - drug therapy Coronary Artery Disease - etiology Coronary Artery Disease - prevention & control Coronary heart disease Fundamental and applied biological sciences. Psychology Heart Hematologic and hematopoietic diseases Humans Letters to the Editor Medical sciences Molecular and cellular biology Piperazines - therapeutic use Platelet Aggregation Inhibitors - therapeutic use Platelet diseases and coagulopathies Prasugrel Hydrochloride Purinergic P2Y Receptor Antagonists - administration & dosage Purinergic P2Y Receptor Antagonists - therapeutic use Risk Reduction Behavior Smoking - adverse effects Smoking - blood Thiophenes - therapeutic use Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Tobacco, tobacco smoking Toxicology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!